In Brief: NDAC September meetings
This article was originally published in The Tan Sheet
NDAC September meetings: FDA formally announces the Sept. 27-28 joint meetings of the Nonprescription Drugs Advisory Committee in the Aug. 22 Federal Register. On Sept. 27, NDAC and the Endocrinologic & Metabolic Drugs Advisory Committee will review Bristol-Myers Squibb's switch NDAs for Questran and Questran Light and discuss issues related to cholesterol-reducing treatments. On Sept. 28, NDAC meets with the Drug Abuse Advisory Committee to discuss SmithKline Beecham's Nicorette (2 mg and 4 mg) and with the Gastrointestinal Drugs Advisory Committee to review Whitehall-Robins' NDA for nizatidine 75 mg ("The Tan Sheet" Aug. 21, pp 1-4). Both meetings begin at 8:30 a.m. in Conference Rooms D & E of FDA's Parklawn Building. On Sept. 29, NDAC will attend a public hearing on OTC labeling reform. A closed session is scheduled for 5-6 p.m. on Sept. 27 with the endocrine committee...
You may also be interested in...
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning